Clear science, from bench to bedside
Laboratory quality systems scrutinise reagents, calibration and competence, yet often leave the instrument clock unexamined. This article sets out why timestamp integrity should be treated as a controlled variable across UK pathology, and how laboratories can assure it before an inspection or serious incident review.
Delta checks can catch a specimen mix-up or a deteriorating patient, but an unvalidated threshold can also stop legitimate results and bury laboratories in alerts. This article sets out a governance model for designing, validating and auditing change-based rules across UK pathology networks.
Laboratories validate the assay and trust the courier, but the hours between the loading bay and the fridge belong to no one. Treating reagent receipt as a controlled process — with defined acceptance checks, excursion decision rules and auditable evidence — is a practical way to close a quiet gap in the diagnostic chain.
Add-on and reflex tests are often treated as minor workflow conveniences, yet they redistribute clinical responsibility, test sample stability and can widen access gaps. This framework sets out how UK laboratories can decide, authorise, audit and publish these rules before they become invisible safety cases.
Networked temperature monitoring has become the default assurance layer for reagents, samples and biobank material. But when every deviation triggers an alert, the signal that matters can disappear into the noise. This audit framework treats cold-chain alarms as a behavioural safety case, not a sensor specification.
Reagent-grade water is often treated as infrastructure rather than an analytical input. This article sets out how biofilm, feed-water shifts, exhausted filters and maintenance windows can alter results in UK biochemistry, microbiology and molecular laboratories, and proposes a practical assurance checklist to use before the next analyser validation.
Field safety corrective actions for in vitro diagnostics often arrive as forwarded emails, portal alerts or dense PDFs rather than dramatic headlines. This article sets out a practical UK laboratory routine for triage, documentation, communication and verification, so that post-market surveillance becomes an active quality process rather than an inbox chore.
A CE mark confirms that a device meets regulatory requirements; it does not confirm that the cohort behind the paperwork resembles the patients in front of you. With assay replacements continuing across UK laboratories in 2026, a structured local-validation protocol can close the distance between certification and clinical reality.
Patients increasingly see blood and pathology results in portals before a clinician has called. For UK laboratories in 2026, that makes release rules, interpretive wording and escalation pathways part of the diagnostic safety case, not an afterthought for communications teams.
Shift change is a clinical transition, not an administrative one. This article sets out why informal bench handover is a diagnostic safety risk in UK laboratories and proposes a one-page ledger that makes outstanding work visible without adding another meeting.
Digital pathology promises resilient reporting and faster second opinions, but scanner colour variation can undermine AI validation and cross-site comparison. This article sets out the colour-assurance questions UK laboratories, vendors and commissioners should answer in 2026.
Preanalytical failure is often treated as a specimen problem, yet many errors are shaped earlier by request forms and electronic ordering screens. This article argues that UK pathology ordering interfaces need device-style scrutiny, with a practical audit and redesign checklist for laboratories, primary care and IT teams.
Unvalidated antibodies rarely announce themselves as procurement failures. They reappear as irreproducible blots, wasted technician hours and grant milestones that cannot be defended. This article sets out a practical validation and lot-tracking framework for UK research teams buying reagents in 2026.
Annual antimicrobial susceptibility updates can reclassify organisms, alter cascade reporting and change clinician behaviour long after the validation paperwork has been filed. This deep dive examines how UK laboratories can manage EUCAST and CLSI revisions across the LIS, disc diffusion, automated systems and stewardship teams without creating invisible reporting inconsistencies.
Home-sampling kits are moving into mainstream UK diagnostics, but a validation pack that stops at the laboratory bench leaves the most variable preanalytical step unexamined. This article sets out a practical transport-stability protocol for blood and saliva kits, from Royal Mail transit profiles to acceptance criteria and the documentation commissioners will expect.
Requests to train AI models on biobank tissue and data expose a gap between broad research consent and machine-learning reuse. This release audit sets out the provenance, commercial-use, re-identification and model-documentation checks UK biobanks should complete before samples leave the freezer.
Vendor reference intervals are convenient defaults, not universal truths. As UK laboratories plan analyzer replacements, local verification and targeted de novo studies can prevent a new platform from redefining disease by configuration.
Vendor throughput claims are measured on a laboratory that does not exist. The informal workarounds and invisible handoffs that hold a real NHS pathology service together are the missing specification — and two weeks of structured observation is cheaper than buying the wrong machine.
Point-of-care testing has moved from the margins of UK diagnostics to something closer to a front door. But a rapid test is not a small laboratory, and scaling community testing depends far less on the device than on the arrangements wrapped around it. A practical checklist for commissioners, pharmacy leads and laboratory teams.
A test with excellent sensitivity can still generate more false positives than true ones once it meets a low-prevalence population. This analysis works through the arithmetic, draws on UK screening and lateral flow experience, and sets out the questions commissioners should ask before adoption.